We therefore hypothesized that our scRNAseq TME insights into the NF1 nerve tumor transcriptome could inform a highly specific, non-invasive circulating proteomic liquid biopsy assay to mitigate the challenges of tissue heterogeneity and enable early MPNST interception. The gene discussed is NF1; the disease is malignant peripheral nerve sheath tumor.